Abstract
BackgroundSpondyloarthritis is associated with impaired physical function, health-related quality of life (HRQL), and work productivity. Adalimumab (ADA) is associated with improved clinical outcomes in patients with peripheral spondyloarthritis (pSpA).ObjectivesTo evaluate...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
